STOCK TITAN

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Amgen (NASDAQ:AMGN) has announced its participation in the 2024 UBS Global Healthcare Conference. Peter Griffith, executive vice president and CFO, will represent the company on Wednesday, Nov. 13, 2024, at 10:15 a.m. PT.

The presentation will be accessible through a live webcast available to investors, media, and the public. The webcast can be accessed on Amgen's website under the Investors section and will remain available for replay for at least 90 days following the event.

Amgen (NASDAQ:AMGN) ha annunciato la sua partecipazione alla 2024 UBS Global Healthcare Conference. Peter Griffith, vicepresidente esecutivo e CFO, rappresenterà l'azienda mercoledì 13 novembre 2024, alle 10:15 PT.

La presentazione sarà accessibile tramite un webcast dal vivo, disponibile per investitori, media e pubblico. Il webcast sarà accessibile sul sito web di Amgen nella sezione Investitori e rimarrà disponibile per la visione on demand per almeno 90 giorni dopo l'evento.

Amgen (NASDAQ:AMGN) ha anunciado su participación en la 2024 UBS Global Healthcare Conference. Peter Griffith, vicepresidente ejecutivo y CFO, representará a la compañía el miércoles 13 de noviembre de 2024, a las 10:15 a.m. PT.

La presentación será accesible a través de un webcast en vivo disponible para inversores, medios y el público. El webcast se podrá acceder en el sitio web de Amgen en la sección de Inversores y permanecerá disponible para su reproducción por al menos 90 días tras el evento.

암겐 (NASDAQ:AMGN)2024 UBS 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 피터 그리피스, 부사장 겸 CFO가 2024년 11월 13일 수요일 오전 10시 15분(PT)에 회사를 대표할 예정입니다.

발표는 투자자, 언론 및 대중이 이용할 수 있는 실시간 웹캐스트를 통해 접근할 수 있습니다. 웹캐스트는 암겐 웹사이트의 투자자 섹션에서 이용 가능하며, 이벤트 후 최소 90일간 다시 보기 기능이 제공됩니다.

Amgen (NASDAQ:AMGN) a annoncé sa participation à la 2024 UBS Global Healthcare Conference. Peter Griffith, vice-président exécutif et CFO, représentera la société le mercredi 13 novembre 2024, à 10h15 PT.

La présentation sera accessible par le biais d'un webinaire en direct disponible pour les investisseurs, les médias et le public. Le webinaire pourra être consulté sur le site web d'Amgen dans la section Investisseurs et restera disponible en replay pendant au moins 90 jours après l'événement.

Amgen (NASDAQ:AMGN) hat seine Teilnahme an der 2024 UBS Global Healthcare Conference bekannt gegeben. Peter Griffith, Executive Vice President und CFO, wird das Unternehmen am Mittwoch, dem 13. November 2024, um 10:15 Uhr PT vertreten.

Die Präsentation wird über ein Live-Webcast zugänglich sein, das für Investoren, Medien und die Öffentlichkeit verfügbar ist. Der Webcast kann auf der Website von Amgen im Bereich Investoren aufgerufen werden und bleibt mindestens 90 Tage nach der Veranstaltung für eine Wiederholung verfügbar.

Positive
  • None.
Negative
  • None.

THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors) 

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-2024-ubs-global-healthcare-conference-302300260.html

SOURCE Amgen

FAQ

When is Amgen (AMGN) presenting at the 2024 UBS Global Healthcare Conference?

Amgen is presenting at the 2024 UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 10:15 a.m. PT.

Who will represent Amgen (AMGN) at the 2024 UBS Healthcare Conference?

Peter Griffith, Amgen's executive vice president and chief financial officer, will present at the conference.

How long will Amgen's (AMGN) 2024 UBS Conference webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.

Where can I watch Amgen's (AMGN) presentation at the 2024 UBS Healthcare Conference?

The presentation can be viewed via webcast on Amgen's website (www.amgen.com) under the Investors section.

Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Stock Data

157.01B
535.91M
0.25%
80.88%
1.64%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS